Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?

References

• Melsen WG, Rovers M, Koeman M, et al. Estimating the attributable mortality of ventilator‐associated pneumonia from randomized prevention studies. Crit Care Med. 2011;39:2736–2742.
   PubMed Web of Science ®Google Scholar
• Mehta AB, Syeda SN, Wiener RS, et al. Epidemiological trends in invasive mechanical ventilation in the United States: a population-based study. J Crit Care. 2015;30:1217–1221.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol. 2012;33:250–256.
   PubMed Web of Science ®Google Scholar
• Luyt C-E, Bréchot N, Combes A, et al. Delivering antibiotics to the lungs of patients with ventilator associated pneumonia: an update. Expert Rev Anti Infect Ther. 2013;11:511–521.
   PubMed Web of Science ®Google Scholar
• François B, Luyt C-E, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 2012;40:1–7.
   PubMed Web of Science ®Google Scholar
• Lu Q, Rouby JJ, Laterre PF, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother. 2011;66:1110–1116.
   PubMed Web of Science ®Google Scholar
• Ramírez-Estrada S, Borgatta B, Rello J. Pseudomonas aeruginosa ventilator-associated pneumonia management. Infect Drug Resist. 2011;9:7–18.
   Google Scholar
• Loke YK, Kwok CS, Niruban A, et al. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax. 2010;65:884–890.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the Clinical Pulmonary Infection Score as a surrogate for diagnostics and outcome. Clin Infect Dis. 2010;51(Suppl 1):S131–S135.
   PubMed Web of Science ®Google Scholar
• Welte T, Dellinger RP, Ebelt H, et al. Concept for a study design in patients with severe community-acquired pneumonia: a randomized controlled trial with a novel IGM-enriched immunoglobulin preparation: the CIGMA study. Respir Med. 2015;109:758–767.
   PubMed Web of Science ®Google Scholar
• Jorens PG. Sticking to an old definition of ventilator-associated pneumonia is not old-fashioned. Respir Care. 2016;61:390–392.
   PubMed Web of Science ®Google Scholar
• Niederman MS, Nair GB. Managing ventilator complications in a ‘VACuum’ of data. Chest. 2015;147:5–6.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54:621–629.
   PubMed Web of Science ®Google Scholar
• Paul M, Bishara J, Yahav D, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ. 2015;350:h2219.
   PubMed Web of Science ®Google Scholar
• Laessig KA. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: Food and Drug Administration perspective. Clin Infect Dis. 2010;51(Suppl 1):S117–S119.
   PubMed Web of Science ®Google Scholar
• Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867–903.
   PubMed Web of Science ®Google Scholar
• Dudeck MA, Horan TC, Peterson KD, et al. National Healthcare Safety Network report, data summary for 2011, device-associated module. Am J Infect Control. 2013;41:286–300.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Povoa P, Rodríguez A, et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Respir Med. 2015;3:859–868.
   PubMed Web of Science ®Google Scholar
• Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36:1089–1096.
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59:51–61.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care. 2012;16:R218.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–710.
   PubMed Web of Science ®Google Scholar
• Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic ‘blind’ bronchoalveolar lavage fluid. Am Rev Respir Dis. 1991;143:1121–1129.
   PubMed Web of Science ®Google Scholar
• Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162:505–511.
   PubMed Web of Science ®Google Scholar
• Luyt C-E, Chastre J, Fagon JY, the VAP Trial Group. Value of the clinical pulmonary infection score for the identification and management of ventilator associated pneumonia. Intensive Care Med. 2004;30:844–852.
   PubMed Web of Science ®Google Scholar
• Schurink CAM, Van Nieuwenhoven CA, Jacobs JA, et al. Clinical pulmonary infection score for ventilator-associated pneumonia: accuracy and inter-observer variability. Intensive Care Med. 2004;30:217–224.
   PubMed Web of Science ®Google Scholar
• Croce MA, Swanson JM, Magnotti LJ, et al. The futility of the clinical pulmonary infection score in trauma patients. J Trauma. 2006;60:523–528.
   PubMedGoogle Scholar
• Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med. 2003;31:676–682.
   PubMed Web of Science ®Google Scholar
• Dennesen PJ, Van der Ven AJ, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med. 2001;163:1371–1375.
   PubMed Web of Science ®Google Scholar
• Luyt C-E, Guérin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med. 2005;171:48–53.
   PubMed Web of Science ®Google Scholar
• Seligman R, Meisner M, Lisboa TC, et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care. 2006;10:R125.
   PubMed Web of Science ®Google Scholar
• Karlsson S, Heikkinen M, Pettilä V, the Finnsepsis Study Group. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care. 2010;14:R205.
   PubMed Web of Science ®Google Scholar
• Brechot N, Hékimian G, Chastre J, et al. Procalcitonin to guide antibiotic therapy in the ICU. Int J Antimicrob Agents. 2015;46:S19–S24.
   PubMed Web of Science ®Google Scholar
• Jenkins SG, Fisher AC, Peterson JA, et al. Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Curr Med Res Opin. 2009;25:3029–3036.
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C, Sollet JP, Schwelch H, et al. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. Clin Infect Dis. 1998;26:346–354.
   PubMed Web of Science ®Google Scholar
• Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68:140–151.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128:3854–3862.
   PubMed Web of Science ®Google Scholar
• Torres A, Ferrer M, Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S48–S53–36.
   PubMed Web of Science ®Google Scholar
• Barbier F, Andremont A, Wolff M, et al. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med. 2013;19:216–228.
   PubMed Web of Science ®Google Scholar
• Bekaert M, Timsit JF, Vansteelandt S, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184:1133–1139.
   PubMed Web of Science ®Google Scholar
• Timsit JF, Zahar JR, Chevret S. Attributable mortality of ventilator-associated pneumonia. Curr Opin Crit Care. 2011;17:464–471.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072–1083.
   PubMed Web of Science ®Google Scholar
• Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J. 2006;27:158–164.
   PubMed Web of Science ®Google Scholar
• Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:657–668.
   PubMed Web of Science ®Google Scholar
• Boucher H, Talbot G, Bradley J, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.
   PubMed Web of Science ®Google Scholar
• Peterson LR. Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis. 2009;49:992–993.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014 [cited 2016 Apr 7]. Available from: http://www.who.int/drugresistance/documents/surveillancereport/en/
   Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009–2012. Int J Antimicrob Agents. 2014;43:328–334.
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
   PubMed Web of Science ®Google Scholar
• Eagye KJ, Kuti JL, Sutherland CA, et al. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US hospitals. Clin Ther. 2009;31:2678–2688.
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis. 2010;50:364–373.
   PubMed Web of Science ®Google Scholar
• Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill. 2014;19(42):pii:20939.
   PubMedGoogle Scholar
• Weterings V, Zhou K, Rossen JW, et al. An outbreak of colistin-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in the Netherlands (July to December 2013), with inter-institutional spread. Eur J Clin Microbiol Infect Dis. 2015;34:1647–1655.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–2328.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20:862–872.
   PubMed Web of Science ®Google Scholar
• Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria. Int J Antimicrob Agents. 2014;43:52–59.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015 [cited 2016 Apr 4]. Available from: http://www.ecdc.europa.eu
   Google Scholar
• Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45:755–773.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Welte T, Wunderink R. Treatment of gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? Crit Care. 2016;20:19.
   PubMed Web of Science ®Google Scholar
• MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58:1359–1364.
   PubMed Web of Science ®Google Scholar
• Crandon JL, Luyt C-E, Chastre J, et al. Pharmacodynamics (PD) of carbapenems for the treatment of P. aeruginosa (PA) ventilator associated pneumonia (VAP), associations with clinical outcome and recurrence. Presented at ICAAC; 2015 Sept 17–21; San Diego, CA. A-468.
   Google Scholar
• Parker SL, Frantzeskaki F, Wallis SC, et al. Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob Agents Chemother. 2015;59:6471–6476.
   PubMed Web of Science ®Google Scholar
• Hites M, Taccone FS, Wolff F, et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother. 2013;57:708–715.
   PubMed Web of Science ®Google Scholar
• Nicolau DP. Optimizing antimicrobial therapy and emerging pathogens. Am J Man Care. 1998;4(Suppl 10):S525–S530.
   Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53:3430–3436.
   PubMed Web of Science ®Google Scholar
• Parker SL, Lipman J, Dimopoulos G, et al. A validated method for the quantification of fosfomycin on dried plasma spots by HPLCMS/MS: application to a pilot pharmacokinetic study in humans. J Pharm Biomed Anal. 2015;115:509–514.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Merelli M, Temperoni C, et al. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob. 2013;12:22.
   PubMed Web of Science ®Google Scholar
• Theravance Biopharma US, Inc. VIBATIV® (telavancin) highlights of prescribing information [cited 2016 Apr 4]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022110s011lbl.pdf
   Google Scholar
• Le J, Ashley ED, Neuhauser MM, et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacother. 2010;30:562–584.
   PubMed Web of Science ®Google Scholar
• Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care. 2007;52:866–884.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Luyt C-E, Nicolau DP, et al. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Int Care. 2016;6:35.
   PubMed Web of Science ®Google Scholar
• Wood C. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Exp Rev Anti-Infect Ther. 2011;9:993–1000.
   PubMed Web of Science ®Google Scholar
• Wood C, Boucher B. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy. 2000;20:166–181.
   PubMed Web of Science ®Google Scholar
• Quon B, Goss C, Ramsey B. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11:425–434.
   PubMedGoogle Scholar
• Hess DR. Nebulizers: principles and performance. Respir Care. 2000;45:609–622.
   PubMedGoogle Scholar
• Rouby J, Bouhemad B, Monsel A, the Nebulized Antibiotic Study Group. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. Anesthesiology. 2012;117:1364–1380.
   PubMed Web of Science ®Google Scholar
• Kollef M, Hamilton C, Montgomery A. Aerosolized antibiotics: do they add to the treatment of pneumonia? Curr Opin Infect Dis. 2013;26:538–544.
   PubMed Web of Science ®Google Scholar
• Dhand R. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv. 2008;21:45–60.
   PubMed Web of Science ®Google Scholar
• Watts AB, McConville JT, Williams RO III. Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm. 2008;34:913–922.
   PubMed Web of Science ®Google Scholar
• Montgomery A, Vallance S, Abuan T, et al. A randomized double-blind placebo-controlled dose-escalation Phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI Investigational eFlow® Inline Nebulizer System in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv. 2014;27:441–448.
   PubMed Web of Science ®Google Scholar
• Montgomery A, Rhomberg P, Abuan T, et al. Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. Antimicrob Agents Chemother. 2014;58:3707–3713.
   Google Scholar
• Montgomery A, Rhomberg P, Abuan T, et al. Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible gram-negative respiratory tract pathogens. Antimicrob Agents Chemother. 2014;58:3714–3719.
   PubMed Web of Science ®Google Scholar
• Hallal A, Cohn SM, Namias N, et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect. 2007;8:73–82.
   PubMedGoogle Scholar
• Kadrichu N, Boc S, Corkery K, et al. In vitro efficiency of Amikacin Inhale, a novel drug-device delivery system. Crit Care. 2013;17(Suppl. 2):P81.
   Google Scholar
• Kadrichu N, Boc S, Day R, et al. Amikacin Inhale: development of a vibrating mesh technology with superior performance. Presented at RDD; 2014 May 4–8; Fajardo, Puerto Rico.
   Google Scholar
• Kadrichu N, Boc S, Corkery K, et al. In vitro assessment of aerosolized amikacin lung dose delivered by NKTR-061 PDDS clinical during on-ventilator and off ventilator use. Presented at ISAM; 2013 Apr 6–10; Chapel Hill, NC. P-055.
   Google Scholar
• Kadrichu N, Boc S, Corkery K, et al. Influence of humidification on in vitro dose delivery for Amikacin Inhale by mechanical ventilation. Presented at ESICM; 2014 Sept 27–Oct 1; Barcelona, Spain. P867.
   Google Scholar
• Corkery KJ, Bacci R, Kadrichu N. Low airborne concentrations following simulated Amikacin Inhale delivery during on-ventilator and hand-held use. Presented at ECCMID; 2013 Apr 27–30; Berlin, Germany. P1636.
   Google Scholar
• So W, Crandon JL, Hamada Y, et al. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem. J Antimicrob Chemother. 2016;71:428–437.
   PubMed Web of Science ®Google Scholar
• Luyt C-E, Clavel M, Guntupalli K, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2009;13:R200, 1–10.
   Web of Science ®Google Scholar
• Luyt C-E, Eldon MA, Stass H, et al. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure. J Aero Med Pulm Drug Del. 2011;24:183–190.
   PubMed Web of Science ®Google Scholar
• Niederman MS, Chastre J, Corkery K, et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with gram-negative pneumonia. Intensive Care Med. 2012;38:263–271.
   PubMed Web of Science ®Google Scholar
• Russell CJ, Shiroishi MS, Siantz E, et al. The use of inhaled antibiotic therapy in the treatment of ventilator-associated pneumonia and tracheobronchitis: a systematic review. BMC Pulmon Med. 2016;16:40.
   PubMed Web of Science ®Google Scholar
• Zampieri FG, Nassar AP, Gusmao-Flores D, et al. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care. 2015;19:150.
   PubMed Web of Science ®Google Scholar